Front Matter; Benign Multiple Sclerosis: A Distinct Clinical Entity with Therapeutic Implications; Pathological Heterogeneity of Idiopathic Central Nervous System Inflammatory Demyelinating Disorders; Multiple Sclerosis Genetics; Imaging of Remyelination and Neuronal Health; Immunological Aspects of Axon Injury in Multiple Sclerosis; The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease; Genetic Analysis of CNS Remyelination; Remyelination in Experimental Models of Toxin-Induced Demyelination
Summary
MS affects nearly 400,000 people in the United States, many of whom are between18 and 40 years of age. With their novel, multifaceted approach to basic science???and their applications in understanding cause and treatment???the authors offer help to clinicians and hope to patients